DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D

Information source: Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Non-Small Cell Lung Cancer

Intervention: Bortezomib (Drug); Acyclovir (Drug)

Phase: Phase 2

Status: Active, not recruiting

Sponsored by: Memorial Sloan Kettering Cancer Center

Official(s) and/or principal investigator(s):
Gregory Riely, MD, PhD, Principal Investigator, Affiliation: Memorial Sloan Kettering Cancer Center

Summary

The purpose of this study is to test the drug Bortezomib to see how well it works. The investigators want to find out what effects, good or bad, it has on patients with a limited smoking history or who have a specific mutation associated with their lung cancer.

Clinical Details

Official title: A Phase 2 Trial of Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D

Study design: Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: efficacy of single-agent subcutaneous bortezomib

Secondary outcome:

Efficacy

Toxicity

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Pathologic or cytologic evidence of non-small cell lung cancer (NSCLC)

- Documented KRAS mutation

- History of smoking < 100 cigarettes (never-smoker) OR patient with a KRAS G12D

mutation regardless of smoking history

- Clinical stage IIIB/IV or recurrent/medically inoperable NSCLC

- Age ≥ 18 years

- Three (3) weeks since last chemotherapy, and three (3) weeks since prior radiation

therapy and recovered from treatment

- Karnofsky performance status ≥ 70%

- Adequate hematologic, and/or hepatic function WBC ≥ 3,000/ul or absolute neutrophil

count ≥ 1,000/ul Hemoglobin ≥ 9. 0 g/dl Platelet count ≥ 100,000/ul AST ≤ 2. 0 X ULN (upper limit of normal)

- Total bilirubin ≤1. 5 x ULN Measurable indicator lesions by RECIST v1. 1 criteria.

- Voluntary written informed consent before performance of any study-related procedure

not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care.

- Female subject is either postmenopausal for at least 1 year before the screening

visit, is surgically sterilized or if they are of childbearing potential, agree to practice 2 effective methods of contraception from the time of signing the informed consent form through 30 days after the last dose of bortezomib, or agree to completely abstain from heterosexual intercourse.

- Male subjects must agree to 1 of the following: practice effective barrier

contraception during the entire study treatment period and through a minimum of 30 days after the last dose of study drug, or completely abstain from heterosexual intercourse. Exclusion Criteria:

- Uncontrolled central nervous system metastases defined as any lesion which is either

a. symptomatic, or requiring escalating doses of corticosteroids

- Significant medical history or unstable medical condition such as uncontrolled

diabetes myocardial infarction within 6 months prior to enrollment New York Heart Association Class III or IV heart failure severe uncontrolled ventricular arrythmias uncontrolled angina ECG evidence of acute ischemia or active conduction system abnormalities

- Baseline ≥ grade 2 peripheral neuropathy by CTCAE v 4. 0 (Appendix B)

- Known hypersensitivity to boron or mannitol

- Female patients who are pregnant/lactating or have a positive serum or urine β-hCG

pregnancy test

- Serious medical or psychiatric illness likely to interfere with participation in this

clinical study.

- No active concurrent malignancy, with the exception of in-situ malignancy completely

resected basal cell carcinoma or squamous cell carcinomas of the skin low-risk prostate cancer after curative therapy

- Participation in clinical trials with other investigational agents not included in

this trial, within 14 days of the start of this trial and throughout the duration of this trial

Locations and Contacts

Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States

Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York 11725, United States

Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States

Memorial Sloan Kettering Cancer Center at Mercy Medical Center, Rockville Centre, New York 11570, United States

Memoral Sloan Kettering Cancer Center at Phelps, Sleepy Hollow, New York 10591, United States

Additional Information

Memorial Sloan Kettering Cancer Center

Starting date: April 2013
Last updated: July 21, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017